Navigation Links
Mpex Pharmaceuticals, Inc. to be Acquired by Axcan
Date:4/14/2011

SAN DIEGO, April 14, 2011 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. announced today that Axcan and Mpex have entered into agreements pursuant to which Axcan will acquire all of the outstanding shares of Mpex and its lead product candidate, Aeroquin™.  A proprietary aerosol formulation of levofloxacin, Aeroquin is currently in Phase 3 clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis (CF).  

All assets not associated with Aeroquin™, including financial and human resources, will be spun out of Mpex and into a newly formed company.  The new company will remain in San Diego and the former personnel of Mpex will continue to lead the Aeroquin clinical development program in collaboration with Axcan.  

Specific financial terms for this transaction were not disclosed but include an upfront payment and a series of payments contingent on regulatory and commercial success.  The full acquisition, which is contingent upon customary closing conditions, is expected to close in the second half of 2011.

"Axcan has a long history of developing and commercializing pharmaceutical products for the cystic fibrosis community, as evidenced most recently by ZENPEP®," stated Daniel Burgess, President and CEO of Mpex.   "We look forward to working with the dedicated team at Axcan to help bring this potentially important new treatment option to patients with CF."

About Mpex Pharmaceuticals

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. Mpex's most advanced product candidate, Aeroquin™ (MP- 376), is a proprietary aerosol formulation of levofloxacin that is currently in Phase 3 clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis.  The Company has a number of additional antibiotic programs designed to address antibiotic resistance in gram negative organisms, including a collaboration with GlaxoSmithKline focused on developing drug candidates utilizing Mpex's efflux pump inhibitor (EPI) technology. Company website: www.mpexpharma.com.

About Axcan 

Axcan, with the recent acquisition of Eurand Pharmaceuticals Inc., is a privately held, leading global specialty pharmaceutical company with clinical, manufacturing and commercial operations in the United States, the European Union and Canada. Axcan develops, manufactures and commercializes pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies used in the treatment of a variety of gastrointestinal and other disorders, including cystic fibrosis. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste-masking/orally disintegrating tablet (ODT) formulations. For more information, visit www.Axcan.com.


'/>"/>
SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer
2. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
3. Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
4. Omthera Pharmaceuticals, Inc. to Present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference
5. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
6. Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray
7. Mangrove Partners Proposes Fully-Financed Dividend Recapitalization to Board of CPEX Pharmaceuticals, Inc.
8. Ferring Pharmaceuticals, Inc. Congratulates R&B and Pop Icon Gloria Gaynor, Named Woman of the Year by Arthritis Foundation
9. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... COUNTY, Calif. , May 3, 2016  While you may be familiar with watching a ... resolution , also known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a ... manufacturer of innovative technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... , May 3, 2016 ... pay $55 million to a woman who says its ... court awarded Gloria Ristesund $5 million in ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... accusations against the company. In February, the same court ...
(Date:5/3/2016)... Intec Pharma Ltd. (NASDAQ: NTEC ... the appointment of Pnina Strauss-Levy as Vice ... has 15 years of experience in clinical research and ... having supported the advancement of several products through the ... the United States and Europe ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... 2016 , ... Healing Cancer in This Century is a Summit ... recovery and is offered by creator and visionary Carlos Caridad. Healing Cancer In ... considering medical and healing modalities of the fields of Integrative, Alternative, Energetic, Holistic ...
(Date:5/3/2016)... ... May 03, 2016 , ... California health startup Pegara announced ... helps people assess their risk of developing Alzheimer’s disease. Using a questionnaire based ... “Risk Reduction Score™” that summarizes how their lifestyle choices may affect their chances ...
(Date:5/3/2016)... ... 03, 2016 , ... With the opioid epidemic now at the forefront, attention ... use. Alcohol and its misuse causes long-term consequences for all aspects of society, ... in those 65 years and older. In addition, there is the long term ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... DNA or RNA from a random library of sequences depending on their attraction ... or diagnostic agents. SELEX selection is commonly performed using filters, panning, or affinity ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... director Joe Ferrazano to serve in the newly created position of executive vice ... the agency’s creative efforts in the Chicago and LA offices. He reports to ...
Breaking Medicine News(10 mins):